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Abstract
TP53 is the most frequently mutated gene in cancers. Mutations lead to loss of p53 expression or expression of a
mutant protein. Mutant p53 proteins commonly lose wild-type function, but can also acquire novel functions in
promoting metastasis and chemoresistance. Previously, we uncovered a role for Rab-coupling protein (RCP) in mutant
p53-dependent invasion. RCP promotes endosomal recycling and signalling of integrins and receptor tyrosine kinases.
In a screen to identify novel RCP-interacting proteins, we discovered P-glycoprotein (P-gp). Thus, we hypothesised that
mutant p53 could promote chemoresistance through RCP-dependent recycling of P-gp. The interaction between RCP
and P-gp was verified endogenously and loss of RCP or mutant p53 rendered cells more sensitive to cisplatin and
etoposide. In mutant p53 cells we detected an RCP-dependent delivery of P-gp to the plasma membrane upon drug
treatment and decreased retention of P-gp substrates. A co-localisation of P-gp and RCP was seen in mutant p53 cells,
but not in p53-null cells upon chemotherapeutic exposure. In conclusion, mutant p53 expression enhanced co-
localisation of P-gp and RCP to allow for rapid delivery of P-gp to the plasma membrane and increased resistance to
chemotherapeutics.
Introduction
During the acquisition of chemoresistance, many cancer
cells upregulate the expression of transporters mediating
drug efflux1,2. Research has therefore focussed on strate-
gies to oppose efflux transporter function3,4. Of these
transporters, P-glycoprotein (P-gp, MDR1, gene: ABCB1)
has received most attention, and overexpression, stabili-
sation as well as polymorphisms in the ABCB1 gene are
associated with chemoresistance4–6. P-gp is involved in
efflux of a range of cellular toxins, and also chemother-
apeutic drugs7,8.
p53 is a tumour suppressor involved in controlling the
balance between cell survival and death upon stresses,
including chemotherapeutics9. p53 is frequently mutated
in a variety of cancers, leading to loss of protein expres-
sion or expression of a mutated protein. Many mutant
p53 proteins acquire gain-of-function properties pro-
moting cell proliferation, metastasis and chemoresis-
tance10. In cells, mutant p53 causes resistance against
chemotherapeutics and mutant p53 expression can be
predictive for patient response to chemotherapy11–18.
These gains-of-function are often the result of mutant p53
interfering with other p53 family members10,19. Pre-
viously, we showed that mutant p53 inhibits p63 and
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thereby promoting Rab-coupling protein (RCP)-depen-
dent invasion and metastasis20,21. Mutant p53 promoted
the interaction between RCP and integrins and facilitated
EGFR signalling to ERK1/2 and Akt. In a screen to detect
novel RCP-interacting proteins, we discovered P-gp. P-gp
has been shown to translocate from the Golgi complex to
the plasma membrane in response to chemotoxic drugs
through regulation via Rab GTPases22–25. However, it is
unknown to what extent this translocation actually plays a
role in chemoresistance.
Here, we describe a novel function for RCP in pro-
moting drug-dependent trafficking of P-gp to the plasma
membrane in mutant p53-expressing cancer cells. These
findings are important because RCP-regulated trafficking
is now established to be a major hub in mutant p53’s pro-
invasive gain-of-function. These findings therefore offer a
basis for the development of RCP-inhibiting drugs that
may simultaneously impair invasiveness and restore
chemosensitivity.
Results
Loss of RCP in mutant p53-expressing cells increases
sensitivity to chemotherapeutics
Previously, we demonstrated that mutant p53 drives
invasion and metastasis by regulating RCP-dependent
recycling of growth factors and integrins. Another gain-
of-function of mutant p53 is chemoresistance and we
therefore determined if RCP promotes mutant p53-
dependent chemoresistance. We used A431 mutant p53
R273H-expressing cells and generated CRISPR control
(ctr, 2 different clones), p53 CRISPR knockout (p53 KO, 2
clones generated from different guide strands) and RCP
CRISPR knockout cells (RCP KO). Next, we investigated
their sensitivity to cisplatin and etoposide using survival
assays. Loss of RCP or p53 decreased cell survival upon
cisplatin and etoposide exposure (Fig. 1A, Supplemental
Tables 1 and 2). Overexpression of GFP-RCP in RCP KO
cells restored survival upon cisplatin and etoposide
exposure, indicating a specific role for RCP in driving
chemoresistance (Fig. 1B, Supplemental Tables 3 and 4).
However, overexpression of GFP-RCP in p53 KO cells did
not restore survival, suggesting that mutant p53 is not
regulating RCP expression levels, but rather a regulatory
pathway that drives RCP function.
Consistent with a decreased cell survival of p53 KO and
RCP KO cells, we also noted a decreased potential to form
colonies upon cisplatin or etoposide exposure (Fig. 1C).
Cisplatin also caused a dose-dependent increase in
cleaved caspase 3 (CC3) that was more pronounced in
RCP KO and p53 KO cells (Fig. 1D and Supplemental
Table 5).
Cisplatin and etoposide resistance could also be observed
in the colon carcinoma cell line HCT116 that expresses
mutant p53 R248W compared to HCT116 p53-null cells
(Supplemental Fig. 1A and Supplemental Table 10). Cis-
platin resistance was RCP-dependent as RCP siRNA
reduced cell viability in response to cisplatin exposure
(Supplemental Fig. 1B and Supplemental Table 10).
Similarly, MDA-MB-231 cells that express a mutant p53
R280K, showed an RCP-dependent resistance to cisplatin
(Supplemental Fig. 1C and Supplemental Table 10). These
data suggest that mutant p53 regulates chemoresistance
in an RCP-dependent manner.
To determine whether loss of p53 or RCP promotes
cisplatin sensitivity in vivo, we generated fluorescent
mCherry-expressing A431 cells and injected these sub-
cutaneously in mice. Tumours were palpable within
2 weeks after injections. Unexpectedly, no tumours with
loss of p53 expression were detected. Loss of RCP was
confirmed in RCP KO tumours, which were significantly
smaller than A431 control tumours (Fig. 2A and Sup-
plemental Fig. 2A). Given that proliferation in culture was
not affected in RCP KO cells and p53 KO cells (Supple-
mental Fig. 2B), these data could indicate that the
knockout cells lack cancer stem cell-like activity as
reported by others26–28. Similarly, we observed that
A431 cells grow fewer numbers and smaller colonies in
anchorage-independent assays upon loss of RCP or
mutant p53 expression (Supplemental Fig. 2C and Sup-
plemental Table 11).
Despite the initial growth differences, we next investi-
gated whether tumours with loss of RCP were more
sensitive to cisplatin treatment. All mice in the control
group with (10/10) or without cisplatin (10/10) developed
tumours. Mice that had received RCP knockout cells all
developed tumours as well (9/9), but in this group only 5
out of 9 mice that were exposed to cisplatin developed
tumours and were measurable by fluorescence (Fig. 2A
and Supplemental Fig. 2D). Cisplatin treatment of RCP
KO tumours resulted in the smallest tumours that were
whiter in appearance when dissected (Supplemental Fig.
2D). Compared to cisplatin treated control tumours, RCP
KO tumours responded about 1.5-fold more to cisplatin
than control tumours, although this was not significant
due to high variation (Fig. 2A). As we detected an increase
in CC3 expression in RCP KO cells compared to control
cells upon cisplatin treatment (Fig. 1D), we next investi-
gated CC3 levels in the xenograft tumours. RCP KO
tumours treated with cisplatin had a significantly larger
number of CC3-positive cells than untreated tumours,
while no difference was observed in CC3 levels in control
tumours treated with or without cisplatin (Fig. 2B).
RCP interacts with P-gp
Previously, we performed a mass spectrometry pro-
teomic screen to identify RCP interaction partners in
H1299 cells21. We detected an interaction between RCP
and P-gp that was more pronounced in mutant p53
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Fig. 1 (See legend on next page.)
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Fig. 2 RCP KO cells are more sensitive to cisplatin in vivo. A mCherry-expressing A431 control and A431 RCP KO cells were injected
subcutaneously and treated with cisplatin (cisplatin 5 mg/kg, intraperitoneally) or a vehicle control. The tumour size was inferred using fluorescence
and quantified using the IVIS software. Error bars indicate SD. Red triangles indicate no measured signal and therefore measurements were set to 0.
Representative images of iRFP signals in mice are shown in the right panels. B Cleaved caspase-3-positive areas were determined in each tumour and
representative images are shown in the left panels, and plotted for each group in the right panel. Error bars indicate SD and * indicates a statistically
significant difference (P= 0.01). Differences between growth rates and fractional cleaved caspase-positive areas were assessed by Mann-Whitney
two-sample statistic with Stata SE 13.1. Scale: 40X.
(see figure on previous page)
Fig. 1 Chemoresistance in A431 cells is dependent on RCP and mutant p53 expression. A Resazurin survival assay of two different ctr
A431 cells, two different p53 KO cells and RCP KO A431 cells in response to increasing doses of cisplatin and etoposide, measured after 96 h.
Statistical differences were measured using a paired two-way ANOVA corrected for multiple testing (two-sided) and IC50 values were measured using
a linear regression analysis. IC50 and P-values can be found in Supplemental Tables 1 and 2. Error bars indicate SD of average values of three
independent experiments with three technical repeats each. Western blot panels are shown on the right incubated for RCP, p53 and GAPDH as
loading control. B Resazurin survival assay of ctr, p53 KO cells and RCP KO A431 cells that were selected for GFP or GFP-RCP expression upon
transfection. Survival was measured 72 h after increasing doses of cisplatin of etoposide, measured after 96 h. Statistical differences were measured
using a paired two-way ANOVA corrected for multiple testing (two-sided) and IC50 values were measured using a linear regression analysis. IC50 and
P-values can be found in Supplemental Tables 3 and 4. Error bars indicate SD of average values of three independent experiments with three
technical repeats each. GFP-RCP expression was verified using western blot (right panels) using RCP and GAPDH as loading control. C A431 ctr1 and
ctr2, p53 KO and RCP KO cells were treated with increasing amounts of cisplatin (top) or etoposide (bottom), allowed to grow in colonies (left panel)
and quantified (right panel). Statistical differences were measured using a paired two-way ANOVA corrected for multiple testing (2-sided). P-values
can be found in Supplemental Table 5. Error bars indicate SD of average values of three independent experiments with three technical repeats each.
D Immunofluorescence and confocal imaging of cleaved caspase 3 (CC3) in A431 ctr1 and ctr2, RCP KO and p53 KO cells upon treatment with
cisplatin for 48 h (4 µM). Automated quantification of CC3 staining per DAPI measured using fluorescence microscopy is shown on the right in a box
and whiskers plot, with mean values indicated. Error bars indicate SD of three independent experiments. * Indicates statistical significance tested
using a t-test, two-sided P < 0.0001 for both.
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R273H cells than in control empty vector cells. This
interaction was validated by immunoprecipitation of GFP-
RCP from GFP-RCP-transfected mutant p53 and p53-null
H1299 cells (Fig. 3A), and again suggested a slightly better
interaction between RCP and P-gp in mutant p53 R273H
cells. The interaction was validated endogenously using
Fig. 3 RCP interacts with P-gp. A H1299 cells, stably expressing mutant p53 R273H or an empty vector (EV) (PCB6) were transfected with GFP or
GFP-RCP and cell lysates were immunoprecipitated with GFP. P-gp and GFP expression was analysed by western blot. B Cell lysates of H1299 cells
stably expressing mutant p53 R273H or an EV (PCB6) were immunoprecipitated with RCP or an IgG control. P-gp and RCP expression was analysed by
western blot. C P-gp and IgG were immunoprecipitated from A431 ctr or A431 KO cells. Endogenous P-gp and RCP protein levels were analysed by
western blot. D P-gp and IgG were immunoprecipitated from HCT116 -/- or 248W cells. Endogenous P-gp and RCP protein levels were analysed by
western blot. E Resazurin survival assay of ctr, p53 KO or RCP KO cells treated with increasing doses of cisplatin and etoposide in combination with
0.5 µM Tariquidar or DMSO control for 96 h. Statistical differences were measured using a paired two-way ANOVA corrected for multiple testing (two-
sided) and IC50 values were measured using a linear regression analysis. IC50 and P-values can be found in Supplemental Tables 6 and 7. Error bars
indicate SD of average values of three independent experiments. F Resazurin survival assay of ctr1 A431 cells treated with increasing doses of
cisplatin or etoposide in the presence or absence of Mab16 (1 µg/mL) for 96 h. Statistical differences were measured using a paired two-way ANOVA
(two-sided) corrected for multiple testing and IC50 values were measured using a linear regression analysis. IC50 and P-values can be found in
Supplemental Table 8. Error bars indicate SD of average values of three independent experiments.
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an RCP pulldown (Fig. 3B), although an increased inter-
action in mutant p53 cells was not observed in this
experiment.
An endogenous interaction between RCP and P-gp was
also observed in A431 cells and in HCT116 cells (Fig. 3C, D).
As endogenous P-gp is not easily detected by western blot, it
is harder to make conclusions as to whether P-gp is inter-
acting stronger with RCP in mutant p53-expressing cells
than in p53-null cells. However, in A431 cells, the RCP co-
immunoprecipitation with P-gp appears weaker than in p53
KO cells (Fig. 3C). In HCT116 cells, less P-gp is immuno-
precipitated by P-gp antibodies in mutant p53-expressing
cells, compared to p53-null cells, although it was difficult to
see P-gp expression in the input. However, co-
immunoprecipitation of RCP by P-gp resulted in a stron-
ger RCP signal in mutant p53-expressing cells, compared to
p53-null cells (Fig. 3D). Together, these results point to P-gp
being an interaction partner of RCP. Our results might
indicate that the RCP/P-gp interaction is more pronounced
in mutant p53-expressing A431 and HCT116 cells than in
p53-null cells. However, it has to be noted that it is difficult
to analyse this interaction in detail. P-gp is a membrane
protein that requires stringent lysis buffer to resolve for
western blot, but such conditions are unfavourable for
maintaining the interaction during immunoprecipitation.
To prove that P-gp is important in mutant p53 and
RCP-mediated chemoresistance, we inhibited P-gp with
the third-generation inhibitor Tariquidar (TQ). A sig-
nificant decrease in cisplatin and etoposide sensitivity was
seen upon TQ treatment (Fig. 3E, Supplemental Tables 6
and 7). Importantly, TQ did not change the sensitivity of
p53 KO or RCP KO to cisplatin or etoposide, suggesting
that mutant p53 and RCP promote chemoresistance in a
P-gp-dependent manner (Fig. 3E).
Others have shown that beta1 integrin inhibition
enhances the sensitivity to chemotherapeutics by pre-
venting activation of EGFR signalling29. As we pre-
viously demonstrated that mutant p53 promotes beta1
integrin and EGFR signalling, we investigated integrin
dependence using Mab16 antibodies that we have shown
to inhibit invasion. These antibodies caused a small
decrease in cisplatin sensitivity, but no change in eto-
poside sensitivity (Fig. 3F and Supplemental Table 8),
suggesting that integrins might play a small role in cis-
platin resistance, but do not play a role in etoposide
resistance.
Previously, others have shown that mutant p53 reg-
ulates P-gp mRNA expression30. We therefore deter-
mined P-gp mRNA and protein levels in A431 cells and
HCT116 cells, but could not detect significant differences
in P-gp mRNA expression upon loss of mutant p53 or
RCP expression in either cell line (Fig. 3C, D and Sup-
plemental Fig. 3A–C). Together, these data suggest that
an interaction between RCP and P-gp in A431 and
HCT116 cells plays a role mutant p53-mediated
chemoresistance.
Mutant p53 promotes RCP and P-gp co-localisation at the
plasma membrane in response to cisplatin
As RCP controls the trafficking of integrins and recep-
tor tyrosine kinases, we determined the cellular localisa-
tion of P-gp in the presence or absence of cisplatin.
Antibodies against endogenous proteins revealed a strong
perinuclear staining for both P-gp and RCP in A431 cells
(Supplemental Fig. 4A). Upon cisplatin treatment a sub-
stantial proportion of P-gp and RCP relocalised to the
plasma membrane (Supplemental Fig. 4A). Importantly,
redistribution of P-gp to the plasma membrane was
strongly diminished following RCP or P-gp knockdown.
(Supplemental Fig. 4A). As the perinuclear part of the
staining for P-gp appeared to be none-specific since it
persisted upon P-gp silencing (Supplemental Fig. 4A
bottom panels), we also used another antibody. This
antibody did not show perinuclear staining, but showed a
stronger membrane staining in general, especially upon
cisplatin incubation, and was reduced upon P-gp silencing
(Fig. 4A and Supplemental Fig. 4B). We used this antibody
to determine P-gp localisation in p53 KO and RCP KO
cells and confirmed that P-gp relocalises to the plasma
membrane in response to cisplatin in mutant p53 cells,
but not in p53 KO or RCP KO cells (Fig. 4A). Interest-
ingly, RCP overexpression did not lead to increased
membrane localisation of P-gp, suggesting that cisplatin is
not increasing RCP expression, but changes RCP function
(Supplemental Fig. 4C).
The close proximity of endogenous P-gp and RCP in
A431 cells was examined using proximity ligation assays
(PLA) (Fig. 4B). Specificity of the signal was determined
using single antibodies (supplemental Fig. 4D) and using
RCP KO cells (Fig. 4B). Loss of p53 in A431 cells strongly
reduced the PLA signal, suggesting that in the absence of
p53, less RCP binds to P-gp. A specific increased mem-
brane co-localisation between RCP and P-gp was also
observed in HCT116 248W mutant p53 cells upon cis-
platin treatment (Fig. 4C and Supplemental Fig. 5A) and a
reduced PLA signal was observed in p53-null HCT116 -/-
cells, compared to mutant p53 248W cells (Fig. 4D). We
also stained MDA MB231 cells for P-gp, but could not
detect a clear membrane signal. As MDA-MB-231 cells
are more elongated and form less cell–cell interactions, it
is likely the signal is too weak to detect on the membrane.
However, in response to cisplatin, intracellular vesicles are
more easily detected in these cells, with a more pro-
nounced co-localisation of RCP and P-gp in peripheral
vesicles (Supplemental Fig. 5B).
To quantify plasma membrane levels of P-gp, we used
flow cytometry using an antibody that recognises the
extracellular domain of P-gp. Specificity was determined
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Fig. 4 Mutant p53 promotes RCP and P-gp co-localisation. A A431 ctr1, A431 RCP KO and A431 p53 KO cells were grown on coverslips and
treated with cisplatin 6.7 µM for 2 h. Localisation of endogenous P-gp and RCP was determined with confocal microscopy using antibodies specific
for P-gp (Invitrogen Ab, green) and RCP (red). Scale bars are 20 µm. B Proximity ligation assays (PLA) in A431 CRISPR control, RCP KO and p53 KO.
Images were taken by confocal microscopy (top). Scale bars are 20 µm. The PLA signal was quantified as dots/nucleus for all the cells and plotted in a
box and whiskers plot (bottom). Statistical differences were measured using a one-way ANOVA, multiple testing corrected P < 0.00001 for both, two-
sided. Error bars indicate SD of average values of three independent experiments (three repeats per experiment). C HCT116 248W cells were grown
on coverslips and treated with cisplatin 6.7 µM for 2 h. Localisation of endogenous P-gp and RCP was determined with confocal microscopy using
antibodies specific for P-gp (Santa Cruz Ab, green) and RCP (red). D Images (left) and quantification (right) of PLA in HCT116 null and 248W cells with
the antibodies specific against P-gp and RCP. Statistical differences were measured using a t-test, P < 0.00001, two-sided. Error bars indicate SD of
average values of three independent experiments (three repeats per experiment).
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using P-gp siRNA (Supplemental Fig. 6A). Cisplatin or
etoposide treatment of mutant p53-expressing cells sig-
nificantly increased the amount of P-gp on the plasma
membrane. This increase was not seen in RCP KO or p53
KO cells upon drug treatment (Fig. 5A–C and Supple-
mental Fig. 6B). Notably, a higher, more variable signal
was observed in p53 KO cells, but the signal did not
further increase in response to drug treatment. These cells
are in general a marginally bigger in appearance and more
irregular, which might explain the slightly higher signal.
Consistent with the findings in A431 cells, a cisplatin-
mediated increase of P-gp at the plasma membrane was
also seen in HCT116 248W cells (Fig. 5D). To prove that
plasma membrane expression upon cisplatin treatment
underlies the mechanism of cisplatin resistance in vivo, we
attempted to stain tumours for P-gp and RCP. Unfortu-
nately, P-gp staining was very low and we could not make
consistent conclusions, but RCP was readily detected.
Interestingly, as observed in cells, cisplatin treatment
lead to an increased membrane staining of RCP in
tumours of 5 out of 10 mice, which was only observed in
1 out of 10 control treated tumours (Fig. 5E). These data
suggest that P-gp and RCP relocate to the plasma
membrane in an RCP-dependent manner in response to
chemotherapeutics.
Recently, it was found that RCP can be phosphorylated
in response to HGF (Hepatocyte Growth Factor)31. Cis-
platin has been shown to increase tyrosine phosphoryla-
tion of several proteins32,33. We therefore investigated if
RCP gets phosphorylated in response to cisplatin. We
used RCP pulldown and examined the presence of p-
tyrosine at the height of RCP in western blots in A431 ctr
and p53 KO cells. We could not detect any increase in
RCP phosphorylation in any of the conditions (Supple-
mental Fig. 6C). These data suggest that RCP is not tyr-
osine phosphorylated in response to etoposide or
Fig. 5 Plasma membrane expression of P-gp is enhanced in mutant p53 cells upon cisplatin treatment. A P-gp plasma membrane expression
was evaluated by flow cytometry of the A431 control and RCP KO cells treated with cisplatin (6.7 µM for 2 h) (left). Fluorescent images of individual
cells are shown on the right, taken after flow cytometry. B Quantification of P-gp plasma membrane expression in A431 ctr1, ctr2, RCP KO and p53 KO
cells upon cisplatin treatment (6.7 µM for 2 h). Statistical differences were measured using a one-way ANOVA, multiple testing ctr1 ± cisplatin P=
0.0001, ctr2 ± cisplatin P= 0.0108, two-sided. Error bars indicate SD of average values of three independent experiments. C Quantification of P-gp
plasma membrane expression in A431 ctr1, ctr2, RCP KO and p53 KO cells upon etoposide treatment (3.4 µM for 2 h). Statistical differences were
measured using a one-way ANOVA, multiple testing ctr1 ± etoposide P < 0.0001, ctr2 ± etoposide P= 0.0002. Error bars indicate SD of average values
of three independent experiments. D P-gp plasma membrane expression in HCT116 p53 248W/- in the presence and absence of cisplatin (6.7 µM for
2 h). Statistical differences were measured using a t-test, two-sided P= 0.0011. Error bars indicate SD of average values of three independent
experiments. E RCP staining in A431 control xenografts from mice exposed to cisplatin or a vehicle control. Numbers of mice that displayed a
membrane staining (including punctate staining), punctate staining only, or low RCP expression are indicated on the right.
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cisplatin, but do not rule out other RCP phosphorylations
in response to chemotherapeutics.
Mutant p53-induced P-gp membrane expression promotes
drug efflux
To determine whether membrane-associated P-gp
facilitated drug efflux, we used two different efflux
assays34, EFFLUX Gold and Calcein. EFFLUX-ID Gold
substrate accumulation was measured after 1 h exposure
in control, p53 KO or RCP KO A431 cells. Loss of either
RCP or mutant p53 caused significant increases in the
intracellular retention of this substrate (Fig. 6A). Similar
results were found using HCT116 248W cells that were
transfected with siRNA to reduce RCP or p53 expression
levels (Fig. 6B), although the absolute amount of substrate
retained was lower.
To determine P-gp specificity, we used a different efflux
assay as the readout is semi-automated microscopy.
Fig. 6 Mutant p53 promotes drug efflux by P-gp. A P-gp export function was determined by EFFLUX-ID Gold in A431 ctr1, ctr2, RCP KO and p53
KO cells. Statistical differences were measured using a paired t-test. ctr1 vs RCP KO, P= 0.0218, ctr2 vs p53 KO, P= 0.006, two-sided. Error bars indicate
SD of three independent experiments. B HCT116 248W/- cells were transfected with 150 pmol of ctr siRNA, siRCP or sip53 for 48 h, followed by
EFLUXX-ID Gold assay. Knockdown was confirmed using western blot to detect RCP and p53. Actin was used as loading control. Statistical differences
were measured using a one-way ANOVA, sictr vs siRCP P= 0.0025, sictr vs sip53 P= 0.0009, two-sided. Error bars indicate SD of average values of
three independent experiments. C Box and whiskers plot showing the calcein AM retention in A431 ctr1, RCP KO and p53 KO cells in response to
0.5 μM Tariquidar (TQ). Individual values of three experiments (three technical repeats) are indicated with error bars representing SD. Statistical
differences were measured using one-way ANOVA with multiple testing (two-sided). P-values are indicated in Supplemental Table 9 for all conditions.
Example images of fluorescent calcein are shown on the right. D Schematic model of RCP function in mutant p53 cells in response to cisplatin. In the
absence of cisplatin RCP resides in the endocytic recycling complex (ERC) and P-gp is dispersed over various intracellular vesicles. In response to
cisplatin, RCP and P-gp relocalised to the plasma membrane in an RCP-dependent manner to facilitate drug efflux.
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We used calcein AM and pre-treated cells with TQ to
inhibit P-gp function. Calcein levels were higher in RCP
KO and p53 KO cells than in control cells (Fig. 6C and
Supplemental Table 10). TQ significantly increased cal-
cein levels in ctr cells to the levels seen in RCP KO cells,
but did not significantly increase the levels in RCP KO
cells (Fig. 6C). The highest levels were observed in p53
KO cells and TQ did not seem to affect calcein levels in
these cells. These data support a role for both mutant p53
and RCP in promoting delivery of P-gp to the plasma
membrane to facilitate drug efflux.
Discussion
We discovered that RCP interacts with P-gp and pro-
motes chemoresistance in mutant p53 cells. Our data
support a model in which P-gp is localised to recycling
endosomes under normal conditions. However, in
response to chemotherapeutics, P-gp relocalises to the
plasma membrane together with RCP to facilitate P-gp
efflux in mutant p53-expressing cells (Fig. 6D).
Previous studies have shown that P-gp is downregulated
by wild-type p53 and upregulated by mutant p5330,35–37.
Our A431 and HCT116 cells did not show a change in P-
gp expression on mRNA or on protein levels between
p53-null and mutant p53 cells. Our results therefore
illustrate that the changes in P-gp resistance to cisplatin
or etoposide were not a result of changes in P-gp
expression levels in these cells. However, in a tumour,
increased P-gp recycling might work in conjunction with
increased P-gp expression and so further enhance che-
moresistance. Some reports suggested a correlation
between mutant p53 and P-gp expression in human
cancers, but others did not find a correlation38–41. Our
work could suggest that in cancers in which a direct
correlation in expression is not found, mutant p53
expression might still be correlated with P-gp plasma
membrane expression and drug efflux.
Only a limited number of studies have investigated the
localisation of P-gp in response to drugs22. Many che-
motherapeutics have been found to be substrates for P-gp,
including etoposide42. However, cisplatin is not a direct
substrate for P-gp, but an increased expression of P-gp in
cisplatin-resistant cell lines or a sensitization to cisplatin
upon downregulation of P-gp has been observed43,44.
DeMeule et al. furthermore detected an increase in the
expression of P-gp at the plasma membrane in vivo in rat
kidneys in response to cisplatin45. P-gp-mediated cisplatin
resistance in mutant p53 cells is what we see in our cell
lines. Interestingly, this resistance coincided with
cisplatin-driven translocation of P-gp to the plasma
membrane that was dependent on RCP and mutant p53.
This raises the question—why does cisplatin drive P-gp to
the plasma membrane, if cisplatin is not directly exported
by P-gp? P-gp has been shown to inhibit apoptosis,
induced by a variety of factors that are not P-gp sub-
strates, including ultrasound46. Although the mechanism
is not fully understood, it is proposed to be linked to
apoptosis-related endogenous substrate efflux. The main
endogenous substrates of P-gp are thought to be oxidised
lipids. Reactive oxygen species are elevated following
cisplatin addition and cisplatin has been shown to change
the lipid composition of the plasma membrane47,48. Our
results, therefore, point towards a role for RCP in deli-
vering P-gp to the plasma membrane to mitigate toxicity
in response to cisplatin. Our study also reveals that eto-
poside, which is a P-gp substrate, results in RCP-
dependent delivery of functional P-gp to the plasma
membrane. In addition, two artificial substrates of P-gp
were retained in cells that had lost RCP or mutant p53
expression. These data strongly point to a role for RCP
recycling of P-gp in chemoresistance.
A remarkable finding in our study is the fact that RCP
KO cells did not form tumours as quickly as control cells
and p53 KO cells did not form tumours in xenograft
studies. This was not expected given that loss of RCP did
not impair tumour growth in other studies31 and loss of
p53 is widely used to generate tumours. Perhaps these
differences can be attributed to the fact that we knocked
out p53 or RCP in cells that had already acquired a gain-
of-function mutation in p53 R273H. Experiments in mice
and cell lines have revealed that cancer cells can become
dependent on p53 mutations and that a loss of mutant
p53 can impair tumour growth and cell survival49,50. This
is in line with the observation that p53 KO and RCP KO
cells were impaired in anchorage-independent growth.
Integrins are involved in the attachment of cells to their
matrix and our previous work detected a decrease in the
recycling of the alpha5/beta1 integrin to the cell surface in
A431 cells that had lost RCP20.These data could therefore
suggest that loss of RCP or p53 in mutant p53 cells
impairs anchoring and settling of the xenografted
tumour cells.
Our data suggest that RCP-dependent endosomal traf-
ficking can regulate the function of several transmem-
brane proteins and thereby impact on the invasion,
metastasis and chemoresistance of mutant p53-expressing
tumour cells. Beta1 integrin has been shown to promote
EGFR recycling and signalling, which led to increased
sensitivity to cisplatin in A549 cells29. We inhibited
integrin recycling using the Mab16 antibody and noticed a
small increase in sensitivity to cisplatin, but not to eto-
poside. These data could indicate that cisplatin resistance
is partly driven in an integrin-dependent manner. It is
interesting that there is a difference between etoposide
and cisplatin, which warrants further investigation into
the details of the RCP interaction with EGFR, integrin and
P-gp in response to different chemotherapeutics. We also
do not exclude the possibility that other transporters are
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regulated by RCP in mutant p53 cells. We validated P-gp
specificity using siRNA targeting P-gp or using TQ, sug-
gesting that the effects we saw were specific for P-gp.
However, other transporters might contribute as well or
regulate resistance to other chemotherapeutics. Other less
well-known ABC transporters were detected in our mass-
spectrometry pulldown experiments and warrant further
investigation.
It will also be important to determine how RCP is
regulated by chemotherapeutics. More recently, RCP was
shown to be phosphorylated by LMTK3 to promote
cell–cell repulsion in response to the growth factor HGF
by regulating EphA2 localisation31. We looked at RCP
tyrosine phosphorylation as cisplatin has been shown to
increase tyrosine phosphorylation EGFR in cancer cells51,
but our p-tyrosine pulldowns did not show any tyrosine
phosphorylation on RCP. Cisplatin has also been shown
to regulate serine phosphorylation of EGFR, leading to
internalisation of EGFR, which was independent of tyr-
osine phosphorylation52. Whether or not RCP is phos-
phorylated upon chemotherapeutic exposure remains to
be elucidated.
To our knowledge this is the first time that RCP is
implicated in chemoresistance in cancer cells. Given that
RCP is a major hub in the regulation of cell invasion and
metastasis, inhibition of RCP could be interesting for
therapeutic intervention in mutant p53 cancer cells.
Materials and methods
Cell lines and culture conditions
H1299, MDA-MB-231 and A431 were obtained from
ATCC (www.ATCC.org). Stable H1299 273H or empty
vector cells were described before20. HCT116 cells were a
gift from Dr. Vogelstein. All cells were cultured in Dul-
becco’s Modified Eagle’s medium (DMEM) (Thermo
Fisher Scientific), supplemented with 10% FBS (Thermo
Fisher Scientific) and 5% pen/strep (Thermo Fisher Sci-
entific) at 37 °C and 5% carbon dioxide. Cells were tested
for mycoplasma and authenticated. Stable clones of
H1299 were generated by transfecting the cell lines using
Genejuice (Merck Millipore) according to manufacturer’s
instruction followed by selection with 600 µg/mL G-418
(Sigma).
Cloning
A web-based CRISPR design tool (http://crispr.mit.edu)
was used for making RCP CRISPR constructs. The fol-
lowing CRISPR guides against RCP were used: fw-
CACCGAAGTACGCCACCTCCGTGT, rev - CAAAA-
CACGGAGGTGGCGTACTTC. Then, 1 µg of pX330
plasmid (Addgene) was digested with 1 U/µL of FastDi-
gest BbsI (Thermo Scientific) restriction enzyme at 37 °C
for 30min in the presence of 1 U/µL Fast alkaline phos-
phatase (Thermo Scientific). The digested plasmid was
agarose gel purified (QIAquick Gel extraction kit, Qia-
gen). Further, each pair of oligos (100 pmol) were phos-
phorylated and annealed in presence of 500 U/µL of T4
polynucleotide kinase at 37 °C for 30min and 95 °C for
5 min and then ramped down to 25 °C at 5 °C/min to form
oligo duplexes. This was followed by a ligation reaction
with digested pX330 plasmid, oligo duplex (1:250) and
quick ligase (New England Biolabs) along with 2X quick
ligation buffer for 10 min at RT. The ligated CRISPR cas9
construct along with RCP specific sequence was trans-
formed in a competent bacteria DH5alpha (NEB).
CRISPR/Cas9-mediated knockouts
The generation of CRISPR KO lines was described by
Mackay et al.53; 10 µg of the above-generated CRISPR
Cas9 RCP construct or pre-made GFP CRISPR constructs
(Sigma, USA) against p53 (TCCATTGCTTGGGACGGC
AAGG) or (GACTGCTTGTAGATGGCCA) empty vec-
tor controls (CRISPR ctr1 and ctr2) were transfected in
A431 cells using lipofectamine® 2000 Transfection
Reagent (Thermo scientific) and Opti-MEM™ I Reduced
Serum Medium (Thermo scientific). p53 KO fluorescent
cells were selected by FACS sorting (BD FACS Aria).
RCP KO cell were selected with 5 µg/mL Puromycin
(Sigma). The cells resistant to the drugs or the sorted cells
were seeded sparsely and clonal colonies were picked up
and verified for their loss of RCP or p53 expression by
SDS-PAGE. Notably, p53 KO A431 cells were cultured in
the DMEM medium supplemented with hydrocortisone
(0.5 mg/mL), cholera toxin (100 ng/mL, Sigma), insulin
(10 µg/mL, Sigma) and EGF (20 ng/mL, Sigma) until
clones were confirmed.
siRNA and transfection procedures
Table 1 lists the used siRNAs. Cells were transfected in
a 6-well dish with 150 pmol ctr, RCP and p53 siRNA or
Table 1 siRNA.
siRNA Sequence Manufacturer





si P-gp_1 GCAGGAAAUUUAGAAGAUC Eurofins
si P-gp_2 UGAGGAUGUUCUGUUAGUA Eurofins
si P-gp_3 UUUUCAUGCUAUAAUGCGA Eurofins
si P-gp_4 CGUUUGUCUACAGUUCGUA Eurofins
si p53 GACUCCAGUGGUAAUCUAC Eurofins
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250 pmol P-gp sRNA along with 6 μl lipofectamine (or
10 μl for P-gp siRNA) Lipofectamine® 2000 and Opti-
MEM™ (Thermo Fisher Scientific) I Reduced Serum
Medium for 72 h. For p53 knockdown, only one siRNA
was used that we have thoroughly investigated for speci-
ficity on all p53 isoforms and that does not interfere in
p63 or p73 expression. For RCP and P-gp knockdown, a
cocktail of 4 siRNAs was used.
Cell viability tests
Cell viability was determined by using MTT cell pro-
liferation kit (R&D systems) on a Tecan Infinite m200 pro
reader at 570 nm absorbance according to the manu-
facturer’s instructions. In all, 10,000 cells were plated
(48 h after siRNA transfection) in 96-well plates and
incubated in cisplatin or etoposide for 72 h. Measure-
ments were done as four technical repeats in three inde-
pendent experiments. Resazurin survival assays were used
to have a larger dynamic range and were measured at
575 nm in the fluorescent channel of a Spectramax
MS5 spectrophotometer (Excitation at 555 nm). Mea-
surements were done as three technical repeats in three
independent experiments. For this assay, 20,000 cells were
cultured per well of 96 wells tissue culture dishes, and
incubated with cisplatin or etoposide for 72 h. GFP RCP
and GFP cells were selected using FACS sorting and
plated 48 h after sorting.
Western blot analysis
Western blot was described previously21. In short,
protein lysates were prepared by washing the cells twice in
ice-cold PBS and lysed on ice with RIPA buffer (1% Ipegal,
1% sodium deoxycholate, 0.1% SDS, 0.15M NaCl, 0.01M
sodium phosphate (pH 7.2)) and supplemented with
complete protease inhibitor tablet (Roche). Lysates were
run on SDS-PAGE and blotted on nitrocellulose. The
blots were probed with the following primary antibodies:
P-gp ((clone G-1), 1:250, Santa Cruz Biotechnology), Rab-
coupling protein (1:1000, D9D8P, Cell Signalling), p53
(DO-1) (1:1000, Santa Cruz Biotechnology) and actin
(1:5000,C2, Millipore). Secondary antibodies were
donkey-anti-mouse 800 or donkey-anti-rabbit 680 and
800 (LI-COR Biotechnology) using the Li-Cor Odyssey,
and anti-mouse HRP conjugated (1:5000, Santa Cruz
Biotechnology). Blots for P-gp expression were developed
with SuperSignal™ Western Blot Enhancer (Thermo
Scientific).
Immunoprecipitation
GFP IPs were described before21. For RCP/ P-gp IPs, cells
from each 10 cm tissue culture dish were lysed by scrapping
in 200 µL of NDLB (5M NaCl, 1M Tris-HCl, pH 7.5, 0.5M
EDTA, 0.5M EGTA, 0.5M NaF, 0.1M NaVO4) and sup-
plemented with complete protease inhibitor tablet, 0.15%
Tween 20 and 10% SIGMAFAST™ Protease Inhibitor
Cocktail Tablet (Sigma). Scraped cells were passed through
a 27.5 G needle (5X) and centrifuged at maximum speed for
10min at 4 °C. For each protein lysate, 40 µL of the sheep-
anti-mouse IgG dynabeads (Thermo scientific) or 40 µL of
the Dynabeads™ Protein G (Thermo scientific) were cou-
pled with antibodies against P-gp (8 µg), GFP (0.75 µg,
Ab6556, Abcam) or RCP (4 µL, D9D8P, Cell Signalling) for
1 h at 4 °C and antibody coupled beads were further incu-
bated with the protein lysates overnight at 4 °C under
constant rotation. Unbound proteins were washed by 4X
washing with the NDLB lysis buffer and eluted in 40 µL of
2X reducing sample buffer and boiled for 10min. One
example is shown, but verified independently in two addi-
tional repeats.
Immunofluorescence, proximity ligation assays and
confocal imaging
Immunofluorescence was described previously53. Cells
were grown on the glass cover slips in 24 wells tissue
culture plate until reaching 70% confluency, washed with
ice-cold PBS and fixed with 4% paraformaldehyde
(Thermo scientific) for 15 min at 4 °C. Cells were washed
with PBS and permeabilised with 0.1% triton-X for 10 min
at RT, blocked in 5% BSA (Sigma) at RT for 1 h, followed
by ON first Ab incubation in block buffer at 4 °C, and 1 h
of secondary Ab. Antibodies were used in the following
dilutions: RCP (D9D8P, Cell Signalling 1:75) and P-gp (SC
31313 1:50, Invitrogen P-gp F4 1:50). Images of one of the
three independent experiments are shown.
For PLA, P-gp (SC 31313) and RCP (D9D8P, Cell Sig-
nalling) were used in the same concentrations as above in
combination with mouse and rabbit plus and minus
probes, according to the manufacturers’ protocol (Duo-
link, Sigma). Images were taken with an inverted confocal
fluorescent microscope (Zeiss). For quantification, >30
fields (6 images per 2 repeats in three independent
experiments) were quantified using ImageJ to calculate
number of dots per nuclei. For quantitative CC3 staining,
96-well plates were imaged and analysed for the CC3
(1:300, Asp175, Cell Signalling) and nuclear staining
(DAPI, Thermo Fisher Scientific) in a Cellomics ArrayS-
can VTI with a HCS Studio 6.6.0 software (Thermo sci-
entific). Images were taken of duplicate samples in three
independent experiments.
Clonogenic assay and anchorage-independent growth
assays
A431 cells were grown for 24 h on 6-well tissue culture
dishes and treated with cisplatin (Santa Cruz Bio-
technology) or etoposide (Sigma). After 24 h of treatment,
1000 cells were seeded per well. Once visible colonies
were formed, colonies were fixed with 4% PFA for 10 min
at 4 °C and stained with 0.01% crystal violet in distilled
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water for 30–45min. Excess of crystal violet was washed
with water and allowed to dry. Plates were scanned in the
Li-Cor Odyssey (700 nm) and colony numbers were
analysed using ImageJ (https://imagej.nih.gov/ij/).
For anchorage-independent growth, 1000 A431 cells
were grown in soft Agar (5%) for 20 days. Colonies were
imaged using bright-field microscopy and colony number
and size were determined using ImageJ in three inde-
pendent experiments (two technical repeats, 3 images per
condition containing >100 colonies each).
EdU staining
A431 CT, RCP KO and p53 KO cells were incubated
with 10 µM EdU for 1 h, fixed, incubated with the Click-
iT® (Click-iT™ EdU (5-ethynyl- 2′-deoxyuridine) Alexa
Fluor™ 488 Flow Cytometry Assay Kit, Life Technologies)
reaction cocktail (30 min, 20 °C), permeabilised with
saponin and counterstained with Hoechst 33342. Cells
were imaged using the PerkinElmer Opera Phenix con-
focal platform. The proportion of green nuclei (EdU) to
blue nuclei (Hoechst 33342) was determined in 4 fields,
each containing 350 cells on average.
P-gp cell surface expression
Cells were treated with cisplatin (6.7 µM) or etoposide
(3.4 µM) for 2 h. Cells were trypsinised, washed 3x with
ice-cold PBS and fixed with 4% PFA for 15min at 4 °C.
Cells were then washed 3x with PBS, blocked in 5% BSA-
PBS at RT for 1 h and incubated in P-gp (1:50) (Pro-
teinTech, 223361) in 1% BSA-PBS overnight at 4 °C. Cells
were then washed 3x with cold PBS and incubated with
secondary antibody (AlexaFluor alpha rabbit 594 1:250,
Life Technologies) in 1% BSA-PBS for 1 h at RT. After 3
PBS washes, P-gp expression was measured by flow
cytometry in three independent experiments.
Efflux assays
P-gp substrate accumulation was determined using
EFLUXX-ID® Gold multidrug resistance assay kit (Enzo
Life Sciences, Inc.) according to the manufacturers’ pro-
tocol and measured by flow cytometry. For Calcein AM
retention, some cells were pre-treated with 0.5 μM TQ for
24 h. Calcein AM was added to a final concentration of
0.01 μM and cells were incubated for 20min at 37 °C in
the incubator. Cells were washed with pre-warmed
medium and incubated for 10min at 37 °C to ensure
optimal retention and 5 μg/mL Hoechst 33342 was added
to stain nuclei in this incubation time. Cells were imaged
on an Opera Phenix high-content screening microscope.
The proprietary software Harmony was used to find the
nuclei (Hoechst) and cell outline of calcein and fluor-
escent intensity of calcein was determined per cell.
Measurements were taken from duplicate wells in three
independent experiments.
Xenografts
Animal experiments were conducted under UK Home
Office licence 70/8655. Six groups of ten 40+ day-old balb/
c nude/male mice (Jackson laboratories), housed at the
Division of Biomedical Services at the University of Leice-
ster were randomly allocated to each group (10 A431
control, 10 A431 control+ cisplatin, 10 A431 RCP KO, 10
A431 RCP KO+ cisplatin) to avoid bias in age and litter of
mice and housed as 5 mice per group with food and water
ad libitum. Numbers per group were based on the variation
seen in a pilot experiment of A431 control cells. Mice were
randomly numbered and all subsequent measures were
done blinded. One mouse was low in weight (<20 g) in the
RCP KO group on the day of cell injections and was
therefore excluded from the study. Another mouse in the
RCP KO group was excluded due to a significant leakage of
cells and no tumour was detected at the end of the study.
For xenograft experiments, 100 µL cell solution containing
10,000 cells and Matrigel (1:1, PBS) was injected sub-
cutaneously in mice anaesthetised with 1.5% isoflurane.
Tumours were grown for 5 days after which cisplatin was
administered intraperitoneally at 5mg/kg, which was
repeated 5 days later. Whole-body fluorescent images (IVIS)
were taken in a blinded manner 12 and 14 days after
xenograft injections, and mice were sacrificed after the last
images were taken when the first tumour reached our
licence maximum stipulated size of 1200mm3 as measured
by calliper measurements. The spectral unmixing tool was
used to separate the fluorophore signal from background
signal in all mice. Prior to imaging, mice were anaesthetised
using 5% isoflurane in oxygen and maintained on 2% iso-
flurane for imaging. Animals were placed in the camera
chamber with sterile eye lubricant. Mice were sacrificed
after the last images and tumours were processed for his-
tology. Fluorescence signals were quantified by using Living
Image v. 4.5 software (PerkinElmer Inc.)
mRNA analysis
For A431 cells, the RNeasy Plus Mini Kit (Qiagen) was
used to isolate RNA according to the manufacturer’s
instructions. cDNA was synthesized using M-MLV
Reverse Transcriptase (Promega) with 1 µg RNA in a
final volume of 20 µL, according to the manufacturer’s
instructions. RT-qPCR was prepared using the Fast SYBR
green master mix (Thermo Scientific) according to the
manufacturer’s instructions in 15 µL and with 1000 nM of
each primer, and run in the QuantStudio 6 Flex Real-
Time PCR System (Thermo Scientific). Cycling condi-
tions: denaturation (95 °C, 3 s), annealing (59 °C, 30 s),
extension (72 °C, 30 s). Primers used (5′ – 3′): GAPDH
fwd: AATCCCATCACCATCTTCCA, GAPDH rev: TGG
ACTCCACGACGTACTCA, P-gp fwd: CCGAACACAT
TGGAAGGAA, P-gp rev – CTTTGCCATCAAGCAG
CAC.
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For HCT116 cells, the Total RNA Purification Kit
(Norgen Biotek) was used to isolate RNA according to the
manufacturer’s instructions. cDNA was synthesized using
the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems) with 1 µg RNA, in a final volume of
20 µL, according to the manufacturer’s instructions. RT-
qPCR was prepared using the PowerUp SYBR Green
Master Mix (Applied Biosystems) according to the man-
ufacturer’s instructions in 15 µL and with 500 nM of each
primer, and run in the QuantStudio 3 Real-Time PCR
System (Thermo Scientific). Cycling conditions: Dena-
turation (95 °C, 5 s), annealing+ extension (60 °C, 20 s).
Primers used (5′ – 3′): GAPDH as for A431 cells, P-gp
fwd: ACAGAGGGGATGGTCAGTGT, P-gp rev –
TCACGGCCATAGCGAATGTT.
Histology, immunohistochemical staining and image
analysis
The tumours were immediately fixed with zinc formalin
(Sigma) overnight at 4 °C and paraffin embedded (FFPE
block). Then, 5 µm sections were taken from each block
and stained with H&E (Sigma) using the Shandon Var-
istain autostainer. Immunohistochemical staining was
performed using a chromogenic DAB method. Assays
were performed on an automated staining platform
(Ventana Discovery Ultra, Roche Tissue Diagnostics/
Agilent Dako Link 48, Agilent) using the conditions
depicted in Table 2, and counterstained with Harris
haematoxylin.
For CC3 quantification, stained slides were imaged at
40x magnification with the Hamamatsu Nanozoomer XR
digital slide scanner and analysed using Visiopharm,
blinded to the researcher. Two analysis protocol packages
were developed: first tumour regions were identified using
a supervised decision forest classification method trained
on the counterstained Immuno Histochemistry image to
outline the tumour as a region of interest. Subsequently,
CC3-positive tumour areas were identified and the per-
centage of CC3 positivity was calculated as, CC3+
tumour area/total tumour area. Percentage of
CC3 staining was calculated as CC3+ tumour area/total
tumour area.
Graphs and statistics
Graphpad Prism was used to make graphs and to
determine statistical differences. Sample size, replicates,
repeats and statistical methods are indicated in the legend
of each figure. For most experiments, three independent
experiments were done with two or three technical
repeats depending on the variation in measurement.
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